Surgery Today

, Volume 41, Issue 7, pp 896–902 | Cite as

Surgical outcomes of intrahepatic cholangiocarcinoma

  • Masakazu Yamamoto
  • Shun-ichi Ariizumi
Review Article


Intrahepatic cholangiocarcinoma (ICC) is considered to be a fatal disease because of frequent recurrence despite curative surgery. The macroscopic classification of ICC in the General Rules for the Clinical and Pathological Study of Primary Liver Cancer of the Liver Cancer Study Group of Japan reflects tumor-spreading patterns; therefore, the clinicopathological findings and surgical outcomes can be predicted using this classification. Lymph node and intrahepatic metastases, and a curative resection are important prognostic factors in ICC; however, lymph node dissection is still controversial. In particular, the intraductal growth type and periductal infiltrating type of ICC without hilar invasion have favorable surgical outcomes, whereas the mass-forming type and periductal infiltrating type of ICC with hilar invasion have high hepatic recurrence and local recurrence, respectively. Multimodal treatments are therefore needed to improve the surgical outcomes of ICC.

Key words

Intrahepatic cholangiocarcinoma Surgical treatment Macroscopic classification Prognostic factors Multimodal treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357.PubMedCrossRefGoogle Scholar
  2. 2.
    Shaib Y, El Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115–125.PubMedCrossRefGoogle Scholar
  3. 3.
    Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303–1314.PubMedCrossRefGoogle Scholar
  4. 4.
    Tomimatsu M, Ishiguro N, Taniai M, Okuda H, Saito A, Obata H, et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993;72:683–688.PubMedCrossRefGoogle Scholar
  5. 5.
    Songsivilai S, Dharakul T, Kanistanon D. Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand. Trans R Soc Trop Med Hyg 1996;90:505–507.PubMedCrossRefGoogle Scholar
  6. 6.
    Yamamoto M, Takasaki K, Nakano M, Saito A. Minute nodular intrahepatic cholangiocarcinoma. Cancer 1998;82:2145–2149.PubMedCrossRefGoogle Scholar
  7. 7.
    Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996;25:933–940.PubMedCrossRefGoogle Scholar
  8. 8.
    Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001;12:959–964.PubMedCrossRefGoogle Scholar
  9. 9.
    Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88:2471–2477.PubMedCrossRefGoogle Scholar
  10. 10.
    Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004;95:592–595.PubMedCrossRefGoogle Scholar
  11. 11.
    Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620–626.PubMedCrossRefGoogle Scholar
  12. 12.
    Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based casecontrol study. Clin Gastroenterol Hepatol 2007;5:1221–1228.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008;14:632–635.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008;103:1716–1720.PubMedCrossRefGoogle Scholar
  15. 15.
    Tao LY, He XD, Qu Q, Cai L, Liu W, Zhou L. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int 2009;30:215–221.PubMedCrossRefGoogle Scholar
  16. 16.
    El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009;49:116–123.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF, Hsieh SY. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009;100:1765–1770.PubMedCrossRefGoogle Scholar
  18. 18.
    Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 2009;15:5976–5982.PubMedCrossRefGoogle Scholar
  19. 19.
    Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 2nd English ed. Tokyo, Japan: Kanehara; 2003.Google Scholar
  20. 20.
    Yamamoto M, Takasaki K, Yoshikawa T, Ueno K, Nakano M. Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma? J Surg Oncol 1998;69:162–167.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003;10:288–291.PubMedCrossRefGoogle Scholar
  22. 22.
    Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR 2003;181:819–827.PubMedGoogle Scholar
  23. 23.
    Morimoto Y, Tanaka Y, Ito T, Nakahara M, Nakaba H, Nishida T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003;10:432–440.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003;10:265–281.PubMedCrossRefGoogle Scholar
  25. 25.
    Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007;37:676–691.PubMedCrossRefGoogle Scholar
  26. 26.
    Aishima S, Kuroda Y, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol 2007;31:1059–1067.PubMedCrossRefGoogle Scholar
  27. 27.
    Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 2001;34:651–658.PubMedCrossRefGoogle Scholar
  28. 28.
    Kim YI, Yu ES, Kim ST. Intraductal variant of peripheral cholangiocarcinoma of the liver with Clonorchis sinensis infection. Cancer 1989;15:1562–1566.CrossRefGoogle Scholar
  29. 29.
    Jang KT, Hong SM, Lee KT, Lee JG, Choi SH, Heo JS, et al. Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection. Virchows Arch 2008;453:589–598.PubMedCrossRefGoogle Scholar
  30. 30.
    Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007;31:2016–2022.PubMedCrossRefGoogle Scholar
  31. 31.
    Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino M. The concept of perihilar cholangiocarcinoma is valid. Br J Surg 2009;96:926–934.PubMedCrossRefGoogle Scholar
  32. 32.
    Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92:2374–2383.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005;29:728–733.PubMedCrossRefGoogle Scholar
  34. 34.
    Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84–96.PubMedCrossRefGoogle Scholar
  35. 35.
    Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:14–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Shimada K, Sano T, Nara S, Esaki M, Sakamoto Y, Kosuge T, et al. Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. Surgery 2009;145:411–416.PubMedCrossRefGoogle Scholar
  37. 37.
    Uchiyama K, Yamamoto M, Yamaue H, Ariizumi S, Aoki T, Kokudo N, et al. Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2010. [Epub ahead of print]Google Scholar
  38. 38.
    DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-oneyear experience with 564 patients at a single institution. Ann Surg 2007;245:755–762.PubMedCrossRefGoogle Scholar
  39. 39.
    Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schönleben F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol 2009;16:404–412.PubMedCrossRefGoogle Scholar
  40. 40.
    Jones S, Thelen A, Benckert C, Biskup W, Neumann U, Rudolph B, et al. Extended liver resection for intrahepatic cholangiocarcinoma. A comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 2009;249:303–309.CrossRefGoogle Scholar
  41. 41.
    Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009;33:1247–1254.PubMedCrossRefGoogle Scholar
  42. 42.
    Nozaki Y, Yamamoto M, Ikai I, et al. Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma. Cancer 1998;83:1923–1929.PubMedCrossRefGoogle Scholar
  43. 43.
    Yamamoto M, Takasaki K, Yashikawa T. Lymph node metastasis in intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 1999;29:147–150.PubMedCrossRefGoogle Scholar
  44. 44.
    Uenishi T, Kubo S, Yamazaki O, Yamada T, Sasaki Y, Nagano H, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg 2008;15:417–422.PubMedCrossRefGoogle Scholar
  45. 45.
    Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002;26:687–693.PubMedCrossRefGoogle Scholar
  46. 46.
    Yamamoto M, Takasaki K, Imaizumi T, Ariizumi S, Matsumura N, Nakano M. A long-term survivor of intrahepatic cholangiocarcinoma with lymph node metastasis: a case report. Jpn J Clin Oncol 2002;32:206–209.PubMedCrossRefGoogle Scholar
  47. 47.
    Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, et al. Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology 2005;52:722–724.PubMedGoogle Scholar
  48. 48.
    Higuchi R, Yamamoto M, Hatori T, et al. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery. Surg Today 2006;36:559–562.PubMedCrossRefGoogle Scholar
  49. 49.
    Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:1145–1151.PubMedCrossRefGoogle Scholar
  50. 50.
    Grobmyer SR, Wang L, Gonen M, Fong Y, Klimstra D, D’Angelica M, et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006;244:260–264.PubMedCrossRefGoogle Scholar
  51. 51.
    Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002;89:1525–1531.PubMedCrossRefGoogle Scholar
  52. 52.
    Lang H, Sotiropoulos GC, Frühauf NR, Dömland M, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005;241:134–143.PubMedGoogle Scholar
  53. 53.
    Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome Am J Surg 2008;196:160–169.PubMedCrossRefGoogle Scholar
  54. 54.
    Portolani N, Baiocchi GL, Coniglio A, Piardi T, Grazioli L, Benetti A, et al. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience. Ann Surg Oncol 2008;15:1880–1890.PubMedCrossRefGoogle Scholar
  55. 55.
    Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008;23:766–770.PubMedCrossRefGoogle Scholar
  56. 56.
    Zhou XD, Tang ZY, Fan J, Zhou J, Wu ZQ, Qin LX, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009;135:1073–1080.PubMedCrossRefGoogle Scholar
  57. 57.
    Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009;16:3048–3056.PubMedCrossRefGoogle Scholar
  58. 58.
    Tamandl D, Kaczirek K, Gruenberger B, Koelblinger C, Maresch J, Jakesz R, et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 2009;96:919–925.PubMedCrossRefGoogle Scholar
  59. 59.
    Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: result in 207 patients. Transplantation 2000;69:1633–1637.PubMedCrossRefGoogle Scholar
  60. 60.
    Robles R, Figueras J, Turrion VS, Margarit C, Moya A, Varo E, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004;239:265–271.PubMedCrossRefGoogle Scholar
  61. 61.
    Ghali P, Marotta PJ, Yoshida EM, Bain VG, Marleau D, Peltekian K, et al. Liver transplantation for incident cholangiocarcinoma. Liver Transpl 2005;11:1412–1416.PubMedCrossRefGoogle Scholar
  62. 62.
    Nakajima T, Kondo Y, Miyazaki M, Okui K. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma. Hum Pathol 1988;19:1228–1234.PubMedCrossRefGoogle Scholar
  63. 63.
    Weinbren K, Mutum SS. Pathological aspect of cholangiocarcinoma. J Pathol 1983;139:217–238.PubMedCrossRefGoogle Scholar
  64. 64.
    Onuki K, Ariizumi S, Ota T, Yamamoto M, Nakano M. Intrahepatic cholangiocarcinoma with micrometastasis in the portal tract in the liver. Clin J Gastroenterol 2009;2:306–309.CrossRefGoogle Scholar
  65. 65.
    Imai K, Yamamoto M, Ariizumi S. Surgery for periductal infiltrating type intrahepatic cholangiocarcinoma without hilar invasion provides a better outcome than for mass-forming type intrahepatic cholangiocarcinoma without hilar invasion. Hepatogastroenterology 2010;58:1333–1336.Google Scholar
  66. 66.
    Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451–461.PubMedGoogle Scholar
  67. 67.
    Hayashi K, Uchida K, Yamamoto M, Yoshitoshi K, Takasaki K. Two cases of bile duct carcinoma which showed remarkable response to a combination of S-1 plus cisplatinum (CDDP). J Appl Res 2005;5:487–491.Google Scholar
  68. 68.
    Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009;250:950–956.PubMedCrossRefGoogle Scholar
  69. 69.
    Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–1281.PubMedCrossRefGoogle Scholar
  70. 70.
    Nathan H, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2010;26:269–273.PubMedCrossRefGoogle Scholar
  71. 71.
    Edge SB. American Joint Committee on Cancer: AJCC cancer staging manual. 7th ed. New York: Springer; 2009.Google Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Masakazu Yamamoto
    • 1
  • Shun-ichi Ariizumi
    • 1
  1. 1.Department of Surgery, Institute of GastroenterologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations